PolyNovo is a worldwide medical machine firm headquartered in Melbourne, Australia. The corporate is recognised within the Innovation, Enterprise Enlargement, and Advertising classes within the 2023 Medical Gadget Community Excellence Awards.
PolyNovo has developed a singular polymer know-how that has marked a major development in biomaterials. Earlier investigations of polymer-based artificial supplies discovered vital challenges in affected person immune responses. Nonetheless, PolyNovo’s know-how, NovoSorb®, options distinctive properties that present glorious biocompatibility, a programmable bio-resorption profile, and may be produced in lots of codecs together with movie, fibre, foam, and coatings.
NovoSorb is the recipient of 40+ patents and has led to the event and manufacture of tissue regenerative options beforehand reserved for biologically primarily based merchandise solely.
A brand new class of dermal matrix
The corporate’s first business product, NovoSorb® BTM, is the world’s first totally artificial dermal matrix that includes a bilayer design for the regeneration of the dermal tissue (a key layer of pores and skin) when misplaced to trauma, surgical procedure, or different accidents. The matrix is totally resorbable forsaking solely the sufferers’ newly shaped tissue. The product provides a easy, but efficient method designed to facilitate a wound mattress that helps dependable wound closure inside a single utility.
An artificial dermal matrix provides vital advantages to present applied sciences. It may be simply manufactured at scale and with much less variance related to tissue processing of biologically derived supplies. Moreover, an artificial doesn’t present any natural materials that may be metabolised by micro organism, which may support clinicians in managing the primary supply of product failure, an infection. Lastly, the structure and bio-resorption profile may be designed particularly to fulfill the wants of its meant use.
As the primary totally artificial dermal matrix, the product has disrupted a number of markets within the superior wound care area by offering a scalable and dependable resolution to sufferers and physicians world wide. Surgeons have discovered it to be simple to make use of, economically worthwhile, and in a position to present dependable outcomes.
“Our outcomes are a vindication of surgeon recognition of constant outcomes, higher affected person expertise together with hospital techniques’ acknowledgement of decrease complexity and value related to NovoSorb BTM”, CEO Swami Raote.
Driving in direction of redefining commonplace of care
The advantages that NovoSorb know-how provides to medical groups have sparked fast curiosity from clinicians world wide. NovoSorb BTM has been clinically investigated in over 200 medical publications with 94% of those being impartial of the corporate. This has led to fast adoption and a fiscal year-on-year (YoY) gross sales development price of over 58%.
The corporate has additionally acquired FDA Breakthrough Gadget Designation and analysis funding from the US Biomedical Superior Analysis and Growth Authority (BARDA) offering creditability to the potential impression of NovoSorb know-how. PolyNovo is worked up about an interim evaluation of its ongoing pivotal research investigating NovoSorb BTM towards the present main remedies of third-degree burns, that are anticipated to be prepared in 2024.
“I really feel so fortunate to have had the [NovoSorb] BTM remedy and I can be without end grateful to the workers for his or her faultless care and wonderful work” – Lowri, Affected person.
Buyer-driven, patient-focused innovation
A monolayer product, NovoSorb MTX lately acquired FDA 510(okay) clearance and launched within the US. The challenge was prioritised primarily based on surgeon buyer suggestions to offer extra versatility and expanded portfolio providing. The launch of NovoSorb MTX marked the institution of an artificial regenerative drugs platform that may provide elevated versatility and worth in soft-tissue reconstruction area. In doing so, PolyNovo expanded its whole addressable market within the US alone by an estimated $A500m ($337m roughly).
“The creation of NovoSorb MTX is an thrilling instance of surgeon-led product growth that opens a major new marketplace for us. We count on clinicians to hold NovoSorb BTM and NovoSorb MTX and supply them with a richer instrument equipment for affected person care.” Swami Raote, PolyNovo CEO.
PolyNovo stewards a sturdy growth programme overlaying soft-tissue reconstruction, breast sling, hernia, and orthopaedic purposes. The corporate’s strategic mindset is to offer the advantages of its know-how to probably the most sufferers, as quickly as attainable. The expansive alternatives NovoSorb know-how provides have led the corporate to accomplice with different entities within the growth of next-generation options.
A world attain
World estimates lead to over 150 million individuals world wide affected by wounds yearly, and solely 11% of the world’s inhabitants has entry to dermal matrices. Given the scalability of an artificial resolution, PolyNovo is concentrated on offering its know-how globally. In 2023, the corporate expanded its presence in India, Hong Kong, UAE, France, Spain, and Canada and has elevated its attain by supporting over 168 new hospitals.
PolyNovo has additionally partnered with organisations world wide to offer options to sufferers in low-access settings to enhance outcomes. After treating over 30,000 sufferers globally, the corporate continues to put money into driving development by way of geographical enlargement, analysis, and growth, and scaling its manufacturing, individuals, and infrastructure, with a view to succeed in the thousands and thousands in want.
PolyNovo is a fast-growing, disruptive medical machine firm which designs, develops, and manufactures regenerative tissue options utilizing its patented biodegradable polymer know-how, NovoSorb. PolyNovo merchandise are at present distributed in 29 nations. PolyNovo is publicly traded on the Australian Inventory Trade (ASX:PNV).
Web site: https://polynovo.com/
E mail: firstname.lastname@example.org
Affected person Testimonials: https://polynovo.com/patient-stories/